Paris, February 3, 2026 – MyC, a software platform dedicated to managing employee health in industrial, multi-site and high-risk environments, announces a €10 million funding round led by European technology investor Hi inov. The transaction also includes IXO and existing investors Elaia and OSS Ventures, and aims to accelerate the development of the platform—particularly its artificial intelligence components—and to support MyC’s international commercial growth.
Founded in 2020 by Dr Laurent Bonnardot, an ENT physician and emergency doctor with extensive experience in isolated and complex environments, and Benjamin Crevant, an entrepreneur from the industrial sector, MyC develops a cloud-based platform that centralises and secures employees’ medical data. The solution enables on-site medical teams and headquarters to coordinate care, manage regulatory obligations, and access a consolidated view of employee health—where operational continuity and compliance are critical.
“For more than twenty years, from industrial sites to offshore platforms, I managed employee health using fragmented systems. Even the world’s largest organisations lacked truly fit-for-purpose tools. MyC was born out of this frustration: providing international companies with a single platform capable of covering all their needs, from on-site medical follow-up to multi-country regulatory compliance, where traditional solutions fall short,” explains Dr Laurent Bonnardot, co-founder of MyC.
A structuring market driven by regulatory and operational pressure
The global occupational health software market is estimated at €1.4 billion and is expected to grow at an average annual rate of nearly 10% through 2033, driven by stricter health and safety regulations, the digitalisation of HR and medical processes, and the increasing number of compliance audits. In many high-risk sectors—such as energy, industry, maritime, defense or specialised medical services—employee health management still largely relies on fragmented tools that are poorly suited to multi-site and international environments.
MyC addresses these challenges by providing an operational response tailored to such contexts. Its platform covers both occupational health and first-line medical care, while ensuring a high level of security and compliance with international standards. It improves operational efficiency through process automation, including pharmaceutical management, medical records management with specialist consultations, and regulatory reporting. Designed to operate in complex conditions, including limited connectivity, the platform enables rapid, large-scale deployments.
A platform adopted by leading international organisations
Based in Paris, MyC employs around thirty people and supports international organisations and major industrial groups in the day-to-day management of employee health across nearly 400 sites in more than 60 countries. The platform has over 1,000 monthly active users and covers more than 500,000 beneficiaries across Europe, the Americas, the Middle East and Africa.
With this funding round, MyC plans to strengthen its product roadmap—particularly around the intelligent use of medical and operational data—and scale its sales and marketing teams to support broader adoption among international enterprise clients.
“MyC addresses a structural challenge for many organisations: gaining access to a reliable, secure and actionable view of employee health in complex, highly regulated environments,” says Valérie Gombart, co-founder and Managing Director of Hi inov. “The platform combines strong domain expertise rooted in medical field experience with a robust SaaS technology designed for international deployment. This investment fully aligns with our strategy to support European B2B companies delivering tangible operational value to essential industries.”
“Since its inception, MyC has been designed for situations where traditional tools—used by only 6% of our clients at the time—reach their limits,” adds Benjamin Crevant, CEO and co-founder of MyC. “This funding will allow us to accelerate platform development, expand its analytical and automation capabilities—particularly through AI—and strengthen our presence among international players facing growing requirements in health, safety and compliance.”